摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Benzyl-N'-(3-dimethylamino-propyl)-carbodiimid | 7521-85-9

中文名称
——
中文别名
——
英文名称
N-Benzyl-N'-(3-dimethylamino-propyl)-carbodiimid
英文别名
1-Benzyl-3-dimethylaminopropylcarbodiimide
N-Benzyl-N'-(3-dimethylamino-propyl)-carbodiimid化学式
CAS
7521-85-9
化学式
C13H19N3
mdl
——
分子量
217.314
InChiKey
ZHVUOIWXIOKFTG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    16
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    28
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Water soluble multi-biotin-containing compounds
    申请人:Wilbur Scott D.
    公开号:US20060228325A1
    公开(公告)日:2006-10-12
    Water-soluble discrete multi-biotin-containing compounds with at least three (3) biotin moieties are disclosed. The water-soluble biotin-containing compounds may additionally comprise one or more moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compounds may include a reactive moiety that provides a site for reaction with yet another moiety, such as a targeting, diagnostic or therapeutic functional moiety. Biotinylation reagents comprising water-soluble linker moieties are also disclosed and may additionally comprise a biotinidase protective group. Methods for amplifying the number of sites for binding biotin-binding proteins at a selected target using multi-biotin compounds also are disclosed.
    可溶于的离散多生物素含有化合物,至少含有三个(3)生物素基团。这些可溶于生物素含有化合物可能还包括一个或多个使其对生物素酶的裂解具有抗性的基团,或者在体外或体内可被裂解的基团。这些离散的多生物素含有化合物可能包括一个反应性基团,提供与另一个基团(如靶向、诊断或治疗功能基团)反应的位点。还公开了包含可溶于的连接基团的生物素化试剂,可能还包括生物素酶保护基团。还公开了使用多生物素化合物扩增在选定靶点上结合生物素结合蛋白的位点数量的方法。
  • NEW METHOD FOR PREPARING 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)BENZENAMINE
    申请人:Esteve Química, S.A.
    公开号:EP3095782A1
    公开(公告)日:2016-11-23
    The present invention relates to a new method for preparing 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-benzenamine. The invention also relates to a new intermediate of formula (XI) used in this method and to a method for preparing nilotinib comprising the step of preparing 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-benzenamine by the method of the invention.
    本发明涉及一种制备3-(4-甲基-1H-咪唑-1-基)-5-(三甲基)-苯胺的新方法。本发明还涉及一种在该方法中使用的新的中间体式(XI),以及一种制备尼洛替尼的方法,其中包括通过本发明的方法制备3-(4-甲基-1H-咪唑-1-基)-5-(三甲基)-苯胺的步骤。
  • Hybrid antibody and process for the production thereof
    申请人:SNOW BRAND MILK PRODUCTS CO., LTD.
    公开号:EP0346087A2
    公开(公告)日:1989-12-13
    A polymer-type hybrid antibody molecule having the capability to recognize two different antigens and a process for the production thereof are disclosed, wherein two kinds of antibody molecules, each having different antigen specificity, are polymerized by cross-linkage of carboxyl groups of carboxyl ends thereof via amino groups. The resultant hybrid antibody can be used, for example, in microdetermination or as a therapeutic agent.
    本发明公开了一种具有识别两种不同抗原能力的聚合物型杂交抗体分子及其生产工艺,其中两种各自具有不同抗原特异性的抗体分子通过基交联其羧基末端的羧基而聚合。由此产生的混合抗体可用于微量测定或用作治疗剂等。
  • Colony stimulating factor-gelatin conjugate
    申请人:DENKI KAGAKU KOGYO KABUSHIKI KAISHA
    公开号:EP0364980A2
    公开(公告)日:1990-04-25
    Disclosed are a crosslinked gelatin microspheres containing CSF and a water soluble CSF-gelatin conjugate. Both the microspheres and the water soluble conjugate provide an improved CSF stability. They have a high potentiation on the antitumor activity of macrophages in respect of the CSF amount and the time required for macrophage activation and are effective in maintaining their activated state for a long period, compared with the native CSF. The mechanism of macrophage activation by the microspheres containing CSF is mediated via phagocytosis and different from that by native CSF, which is believed to activate macrophages via cell surface receptor. The species specificity of CSF may be absrogated when the CSF is internalized into macrophages through hagocytosis.
    本发明公开了一种含有 CSF 的交联明胶微球和一种溶性 CSF-明胶共轭物。微球和溶性共轭物都能提高 CSF 的稳定性。与原生 CSF 相比,它们对巨噬细胞的抗肿瘤活性具有很高的增效作用,与巨噬细胞活化所需的 CSF 量和时间相比,它们能长期有效地维持巨噬细胞的活化状态。含有 CSF 的微球激活巨噬细胞的机制是通过吞噬作用介导的,与原生 CSF 不同,原生 CSF 被认为是通过细胞表面受体激活巨噬细胞的。当 CSF 通过吞噬作用内化到巨噬细胞中时,CSF 的物种特异性可能会消失。
  • Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
    申请人:Rutgers, The State University of New Jersey
    公开号:US20020035217A1
    公开(公告)日:2002-03-21
    Polymeric micelles for encapsulation of hydrophobic molecules are provided. Methods and formulations for delivering hydrophobic molecules to a host via these micelles are also provided. Methods of stabilizing liposomes or lipid based formulations by addition of polymeric micelles are also provided.
    提供了用于封装疏分子的聚合物胶束。还提供了通过这些胶束向宿主输送疏分子的方法和制剂。还提供了通过添加聚合物胶束稳定脂质体或脂基制剂的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫